Volume 86 Issue 10 | p. 29 | Concentrates
Issue Date: March 10, 2008

PDL To Restructure After Sale Failed

Department: Business | Collection: Sustainability

PDL BioPharma has ended a strategic review in which it tried to sell itself and will instead remain an independent company focused on developing antibodies for cancer and immunologic diseases. During the review, the biotech firm sold assets worth more than $525 million. It will distribute much of this cash to shareholders. PDL cut 320 jobs through the asset sales and now says it will cut another 260 positions. The firm expects to end up with about 300 employees.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment